Anebulo Pharmaceuticals (ANEB) Expected to Announce Earnings on Wednesday

Anebulo Pharmaceuticals (NASDAQ:ANEB) is expected to release its Q3 2025 earnings data before the market opens on Wednesday, May 21st. Analysts expect Anebulo Pharmaceuticals to post earnings of ($0.05) per share for the quarter.

Anebulo Pharmaceuticals (NASDAQ:ANEB) last posted its earnings results on Tuesday, May 13th. The company reported ($0.04) EPS for the quarter, topping the consensus estimate of ($0.05) by $0.01.

Anebulo Pharmaceuticals Price Performance

Anebulo Pharmaceuticals stock opened at $1.06 on Tuesday. The company has a market capitalization of $43.55 million, a price-to-earnings ratio of -3.79 and a beta of -1.12. Anebulo Pharmaceuticals has a one year low of $0.80 and a one year high of $3.08. The company’s fifty day moving average price is $1.19 and its two-hundred day moving average price is $1.37.

Institutional Investors Weigh In On Anebulo Pharmaceuticals

A hedge fund recently bought a new stake in Anebulo Pharmaceuticals stock. Goldman Sachs Group Inc. purchased a new stake in shares of Anebulo Pharmaceuticals, Inc. (NASDAQ:ANEB) in the first quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor purchased 47,954 shares of the company’s stock, valued at approximately $62,000. Goldman Sachs Group Inc. owned 0.12% of Anebulo Pharmaceuticals at the end of the most recent reporting period. 28.40% of the stock is owned by institutional investors and hedge funds.

Wall Street Analysts Forecast Growth

Separately, Maxim Group lowered their target price on shares of Anebulo Pharmaceuticals from $6.00 to $3.00 and set a “buy” rating on the stock in a research report on Thursday, May 15th.

About Anebulo Pharmaceuticals

Anebulo Pharmaceuticals, Inc, a clinical-stage biotechnology company, engages in developing solutions for people suffering from acute cannabinoid intoxication (ACI) and substance addiction. The company's lead product candidate is ANEB-001, a small molecule cannabinoid receptor antagonist, which is in a Phase II clinical trial to address the unmet medical need for a specific antidote for ACI.